{"classes":[{"categories":[{"measurements":[{"comment":"Not Applicable - not all participants had an event at time of analysis, max time censored","groupId":"OG000","lowerLimit":"0","upperLimit":"NA","value":"5.5"},{"comment":"Not Applicable - not all participants had an event at time of analysis, max time censored","groupId":"OG001","lowerLimit":"0","upperLimit":"NA","value":"6.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"374"},{"groupId":"OG001","value":"362"}],"units":"Participants"}],"description":"Median time (in months) from randomisation until objective disease progression or death (in the absence of objective progression).","dispersionType":"Full Range","groups":[{"description":"Fulvestrant 250 mg Intramuscular Injection every 28 days","id":"OG000","title":"Fulvestrant 250 mg"},{"description":"Fulvestrant 500 mg Intramuscular Injection every 28 days plus 500 mg on day 14","id":"OG001","title":"Fulvestrant 500 mg"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"RECIST(Response Evaluation Criteria in Solid Tumors ) tumour assessments carried out every 12 weeks (+/- 2 weeks) from randomisation for study duration (48 months)","title":"Time to Progression (TTP)","type":"PRIMARY","unitOfMeasure":"months"}